Home > Insider Trading > Filing (0001209191-23-002179)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	Biological Products, (No Disgnostic Substances) (2836)	463872213

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1724310	J. Ryan Watts	C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-01-03	82,240	$0.00	231,934	No	4	A	Direct
Common Stock	Disposition	2023-01-04	5,029	$28.73	2,213,464	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2023-01-03	246,720	$0.00	246,720	$27.63

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
246,720		2033-01-02	No	4	A	Direct

Footnotes

Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2024 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 15,500 RSUs held by the Reporting Person.
Includes 231,934 RSUs.
Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.58 to $29.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
25% of the shares subject to the option shall vest on January 3, 2024, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.